Cortex Pharmaceuticals Inc.
15241 Barranca Parkway
Irvine,
CA 92618
United States - Map
Phone: 949-727-3157
Fax: 949-727-3657
Web Site: http://www.cortexpharm.com
| Index Membership: | N/A | | Sector: | N/A | | Industry: | N/A | | Full Time Employees: | 13 |
|
| Cortex Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company develops AMPAKINE compounds for the treatment of Alzheimers disease, mild cognitive impairment, attention deficit hyperactivity disorder, schizophrenia, depression, respiratory depression caused by opiate analgesics, and possibly sleep apnea. Its low impact AMPAKINE compounds include CX717 and CX1739, which are in phase II clinical development stage; and high impact compounds include CX929 for Huntingtons disease patients. The company has a research collaboration and exclusive worldwide license agreement with NV Organon to develop and commercialize its AMPAKINE technology for the treatment of schizophrenia and depression. Cortex Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Roger G. Stoll Ph.D., 65
Exec. Chairman |
$
370.00K |
$
0 | Dr. Mark Varney Ph.D., 42
Chief Exec. Officer, Pres, Director and Member of R&D Committee |
$
347.00K |
$
0 | Dr. Carl W. Cotman Ph.D., 69
Co-Founder, Scientific Director, Consultant, Director and Chairman of R&D Committee |
$
20.00K | N/A | Ms. Maria S. Messinger CPA, 42
Chief Financial Officer, Principal Accounting Officer, VP, Corp. Sec. and Controller |
$
243.00K |
$
0 | Dr. Pierre V. Trân M.D., M.M.M., 49
Chief Medical Officer and VP of Clinical Devel. |
$
305.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.63% Nasdaq 
0.03%
Profile
